Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of TST001 plus nivolumab and chemotherapy as first-line treatment for Claudin18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma
CTR20232736Phase 3Active
- Sponsor
- Transcenta
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of osemitamab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Transcenta. Started Sep 2023; status: active.
02
Drugs
osemitamab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20232736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232736.